Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow G61 1QH, UK.
Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
Cell Rep. 2020 Feb 25;30(8):2729-2742.e4. doi: 10.1016/j.celrep.2020.01.080.
Pancreatic ductal adenocarcinoma (PDAC) features a near-universal mutation in KRAS. Additionally, the tumor suppressor PTEN is lost in ∼10% of patients, and in mouse models, this dramatically accelerates tumor progression. While oncogenic KRAS and phosphatidylinositol 3-kinase (PI3K) cause divergent metabolic phenotypes individually, how they synergize to promote tumor metabolic alterations and dependencies remains unknown. We show that in KRAS-driven murine PDAC cells, loss of Pten strongly enhances both mTOR signaling and macropinocytosis. Protein scavenging alleviates sensitivity to mTOR inhibition by rescuing AKT phosphorylation at serine 473 and consequently cell proliferation. Combined inhibition of mTOR and lysosomal processing of internalized protein eliminates the macropinocytosis-mediated resistance. Our results indicate that mTORC2, rather than mTORC1, is an important regulator of protein scavenging and that protein-mediated resistance could explain the lack of effectiveness of mTOR inhibitors in certain genetic backgrounds. Concurrent inhibition of mTOR and protein scavenging might be a valuable therapeutic approach.
胰腺导管腺癌 (PDAC) 的特征是 KRAS 近乎普遍发生突变。此外,肿瘤抑制因子 PTEN 在约 10%的患者中丢失,在小鼠模型中,这极大地加速了肿瘤的进展。虽然致癌 KRAS 和磷脂酰肌醇 3-激酶 (PI3K) 单独引起不同的代谢表型,但它们如何协同促进肿瘤代谢改变和依赖性仍然未知。我们表明,在 KRAS 驱动的小鼠 PDAC 细胞中,Pten 的缺失强烈增强了 mTOR 信号和巨胞饮作用。通过挽救 AKT 丝氨酸 473 处的磷酸化,从而恢复细胞增殖,蛋白吞噬作用缓解了对 mTOR 抑制的敏感性。我们的结果表明,mTORC2 而不是 mTORC1 是蛋白吞噬作用的重要调节剂,并且蛋白介导的耐药性可能解释了在某些遗传背景下 mTOR 抑制剂缺乏有效性的原因。同时抑制 mTOR 和内化蛋白的溶酶体处理可能是一种有价值的治疗方法。